Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10795544 | 0.91 | FOXM1 (0.57) | MAOBNPC1RAB9ALTA4HEPHX2 | |
| SCHEMBL10791453 | 0.86 | FFAR1 (0.48) | MAOBFFAR1 | |
| SCHEMBL15079872 | 0.84 | NPC1 (0.69) | MAOBNPC1RAB9ALTA4HFFAR1 | |
| SCHEMBL6852321 | 0.84 | LMNA (0.64) | MAOBAPPNPC1RAB9ALTA4H | |
| SCHEMBL320679 | 0.83 | ADRB2 (0.54) | MAOBAPPMEN1ALDH1A1KMT2A | |
| SCHEMBL4337813 | 0.82 | MEN1 (0.68) | MAOBAPPRAB9AMEN1ALDH1A1 | |
| SCHEMBL10652905 | 0.81 | NPC1 (0.58) | NPC1RAB9ALTA4HMEN1ALDH1A1 | |
| SCHEMBL6282133 | 0.81 | NPC1 (0.58) | MAOBNPC1RAB9ALTA4HEPHX2 | |
| SCHEMBL4743351 | 0.80 | LTA4H (0.69) | MAOBLTA4HEPHX2FFAR1FFAR4 | |
| SCHEMBL10792214 | 0.80 | LMNA (0.59) | APPNPC1RAB9ALTA4HMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | MAOB 1022/4885APP 1892/4885NPC1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.